CRO Industry – Q4 2022 Update & Competitive Differentiation

  • Public Equity
  • Healthcare
  • North America


Founder & consultant at a CRO consultancy


  • Trends and Developments in the CRO (contract research organisation) market, highlighting Iqvia (NYSE: IQV), PPD (NASDAQ: PPD), Icon (NASDAQ: ICLR), Syneos Health (NASDAQ: SYNH), and Medpace (NASDAQ: MEDP)
  • Purchasing criteria for pharmaceutical and biotech customers and differentiators for large market CRO services, highlighting expertise in a particular therapeutic area, global geographic reach and pre-clinical and clinical capabilities
  • CROs’ DCT (decentralised clinical trial) capabilities, discussing remote technology and data collection
  • M&A in the CRO sector – Icon’s July 2021 acquisition of PRA and projected strategic M&A opportunities as CRO industry grows
  • Industry contracting models, discussing product-based services vs outcome-based models, plus 12-18-month CRO market outlook and increased adaptation of emerging technologies


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited